Table 3.
Univariate analysis for association of baseline characteristics and therapeutic response with PFS and OS from start of PLD.
| Characteristics | Number of patients | Median PFS, months | P value | Median OS, months | P value |
|---|---|---|---|---|---|
| All | 129 | 5.8 | 14.2 | ||
| Age | |||||
| < 63 | 64 | 5.7 | 0.147 | 12.5 | 0.776 |
| ≥63 | 64 | 7.3 | 14.6 | ||
| Age | |||||
| < 50 | 17 | 4.0 | 0.247 | 16.6 | 0.880 |
| ≥50 | 112 | 6.0 | 14.2 | ||
| No. cardiac risk factors | |||||
| 1 - 2 | 88 | 5.3 | 0.997 | 14.5 | 0.163 |
| ≥3 | 41 | 6.4 | 11.1 | ||
| No. metastatic sites | |||||
| 1-3 | 99 | 7.1 | 0.021 | 15.3 | < 0.001 |
| 4-7 | 30 | 3.6 | 6.0 | ||
| Metastatic site | |||||
| Visceral | 92 | 5.4 | 0.034 | 12.5 | 0.618 |
| Nonvisceral | 37 | 9.8 | 14.3 | ||
| Prior endocrine therapy | |||||
| No | 33 | 5.4 | 0.305 | 14.8 | 0.061 |
| Yes | 96 | 6.0 | 12.4 | ||
| No. of prior chemos+ | |||||
| 0 - 3 | 95 | 7.3 | 0.001 | 14.5 | 0.01 |
| ≥4 | 34 | 5.0 | 10.1 | ||
| Prior anthracycline | |||||
| No | 52 | 7.8 | 0.104 | 15.1 | 0.057 |
| Yes | 77 | 5.7 | 10.1 | ||
| Prior taxane | |||||
| No | 56 | 7.8 | 0.036 | 14.3 | 0.392 |
| Yes | 73 | 5.4 | 12.5 | ||
| Response | |||||
| CR/PR | 34 | 10.0 | < | 17.5 | < 0.001 |
| SD | 24 | 11.9 | 0.001 | 24.6 | |
| PD | 62 | 2.8 | 8.6 | ||
| NE | 9 | 2.4 | 3.0 | ||
| PLD extension* | |||||
| 6 cycles, no extension | 31 | 9.8 | 0.466 | 21.3 | 0.516 |
| > 6 cycles | 17 | 10.9 | 24.2 | ||
*Patients who achieved SD, PR or CR after scheduled PLD (i.e., 6 cycles). +Adjuvant chemotherapy was counted as prior therapy line.